We were interested in the recent study by Rujkijyanont and Inaba that examines the challenges in diagnosing and treating pediatric acute lymphoblastic leukemia (ALL) in low- and middle-income countries [1]. The study indicates that limited resources in low- and middle-income countries lead to suboptimal outcomes compared to high-income countries, where advances in diagnostics and treatment have markedly improved survival rates [1]. These findings underscore the disparities in ALL management and outcomes across different income levels.

Recent research and data indicate that global efforts to prevent and treat pediatric ALL still require increased attention to resource allocation and healthcare inequities [2]. Inspired by their research, we conducted our own analysis using Global Burden of Disease data [3]. We employed the Estimated Annual Percentage Change (EAPC) to assess trends from 1990 to 2021, focusing on the disparities in ALL incidence and mortality among children aged 0–14 across countries with different income levels [4]. Our supplementary analysis aims to provide deeper insights into these disparities and contribute to the ongoing discussion on improving global treatment outcomes for pediatric ALL.

我们对 Rujkijyanont 和 Inaba 最近的研究感兴趣，该研究考察了低收入和中等收入国家诊断和治疗儿科急性淋巴细胞白血病 （ALL） 的挑战 [1]。研究表明，与高收入国家相比，低收入和中等收入国家的资源有限会导致结果欠佳，而高收入国家在诊断和治疗方面的进步显著提高了生存率 [1]。这些发现强调了不同收入水平在 ALL 管理和结果方面的差异。

最近的研究和数据表明，全球预防和治疗儿科 ALL 的努力仍然需要更多地关注资源分配和医疗保健不平等 [2]。受他们研究的启发，我们使用全球疾病负担数据进行了自己的分析 [3]。我们采用估计年度百分比变化 （EAPC） 来评估 1990 年至 2021 年的趋势，重点关注不同收入水平国家 0-14 岁儿童 ALL 发病率和死亡率的差异 [4]。我们的补充分析旨在更深入地了解这些差异，并为正在进行的关于改善儿科 ALL 全球治疗结果的讨论做出贡献。